reconstitution comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-01. Numbers and descriptions here follow the published literature rather than marketing material.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
In 1981, Frank D. Hickingbotham (b. 1936) opened the first TCBY in Little Rock, Arkansas. TCBY began franchising the following year, and had expanded to over 100 locations by 1984. Prior to 1984, the company's name was "This Can't Be Yogurt," but a lawsuit from a competitor, I Can't Believe It's Yogurt!, forced TCBY to create a new name from its initials, eventually using "The Country's Best Yogurt". TCBY began co-branding with Taco Bell, McDonald's, Subway, and Burger King in 1995. In 1991 TCBY moved into the tallest building in Arkansas, the forty-story Simmons Tower located in downtown Little Rock, and the building was renamed The TCBY Tower until 2000 when TCBY vacated. Mrs. Fields acquired TCBY in early 2000 and became Mrs. Fields Famous Brands. The combined company relocated headquarters to Broomfield, Colorado in 2012. TCBY was also present in Honduras, Costa Rica and Nicaragua for several years, but closed all of its branches. In 2001, there were 1,777 TCBY locations across the United States. By 2011, after several waves of closings, there were 405.
== Competitiveness == The Global Competitiveness Report 2019 published by the World Economic Forum, ranked 141 nations for national competitiveness, defined as the set of institutions, policies and factors that determine productivity. Thailand ranked 40 of 141 (1=best). Other ASEAN nations ranked were: Singapore, 1; Malaysia, 27; Indonesia, 50; Brunei, 56; Philippines, 64; Vietnam, 67; Cambodia, 106; Laos, 113. IMD World Competitive Rankings 2019: Ranked Thailand 25 of 63 nations (1=most competitive). Other ASEAN nations were ranked: Singapore, 1; Malaysia, 22; Indonesia, 32; Philippines, 46. Global Competitiveness Index (GCI) 2014-2015: Thailand ranked 32 of 140 economies in the World Economic Forum's GCI. It was ranked sixth in ASEAN+3 (China, Japan, South Korea). ASEAN partners Singapore ranked second and Malaysia 18th. IMD World Competitiveness Yearbook 2016: Thailand rose two places from 2015's ranking to rank 28 of 61 nations (1=best, 61=worst) in competitiveness. IMD World Competitiveness Yearbook 2015: Thailand ranked 30 of 61 nations. The ranking looks at 20 areas grouped around four main topics: economic performance, government efficiency, business efficiency, and infrastructure. Thailand's ranking in health and environment is its lowest, 54th. The best ranking is in the employment area (3rd) thanks low unemployment. Among 61 economies, Thailand's business legislation is also ranked poorly, at 51. In education, it is ranked 48.
The surgical management of nasal defects and deformities divides the nose into six anatomic subunits: (i) the dorsum, (ii) the sidewalls (paired), (iii) the hemilobules (paired), (iv) the soft triangles (paired), (v) the alae (paired), and (vi) the columella. Surgical correction and reconstruction comprehend the entire anatomic subunit affected by the defect (wound) or deformity, thus, the entire subunit is corrected, especially when the resection (cutting) of the defect encompasses more than 50 percent of the subunit. Aesthetically, the nose—from the nasion (the midpoint of the nasofrontal junction) to the columella-labial junction—ideally occupies one-third of the vertical dimension of the person's face; and, from ala to ala, it ideally should occupy one-fifth of the horizontal dimension of the person's face. The nasofrontal angle, intersection of the line from the nasion to the nasal tip with the line from the nasion to the glabella, usually is 115-130 degrees; the nasofrontal angle is more acute in the male face (115-120°) than in the female face (120-130°). The nasofacial angle, intersection of the line from the nasion to the nasal tip with the line from the nasion to the pogonion, is approximately 30–40 degrees, and this angle is roughly similar between men and women. The nasolabial angle, the intersection of the line of the columella and the line from the subnasale to upper lip (eg, philtrum), is approximately 90–95 degrees in the male face, and approximately 100–105 degrees in the female face.
Oshkosh, Wisconsin, franchise manager Jim Brajdic said: "Problems back then, including a lawsuit, franchisee discontent, and inconsistencies in the operation, caused the chain to flounder and branches to close." A&W moved to a modern-style franchise agreement that introduced royalty payments and new standards. However, many franchisees refused the revised terms as their 20- or 25-year original agreements expired. In 1980, the number of restaurants had fallen to 1,300 in the United States (mostly in the Midwest and the North West), Asia, and Europe. In 1980, the Singaporean franchisee Temenggong Ltd. had increased the number of restaurants in the country, while nine new restaurants were planned in Malaysia. There were also plans to open restaurants in the Philippines and Hong Kong. Negotiations to sell the chain began in November 1981.
== Mechanics of Micronization == The size reduction achieved by mechanical micronization depends on both the mill and the material being ground. The breakage behaviour of a material can be characterised by material parameters derived from single-particle impact tests, which quantify a particle's resistance to fracture and the minimum specific energy it can absorb without breaking; these allow the breakage probability of different materials to be described by a common master curve.
Sources: en.wikipedia.org
== Properties == Vitamers often have subtly different properties from their primary, or most common form. These differences include abundance in the typical diet, bioavailability, toxicity, physiological activities, and metabolism. Some vitamers are associated with different benefits for health compared to other forms of the same vitamin. Folic acid, a vitamer of vitamin B9 commonly added to fortified foods and dietary supplements, is 0.7–1.0 times more bioavailable than vitamers of vitamin B9 found in minimally processed foods. Differences in digestion and absorption account for the notable differences in bioavailability between vitamers of vitamin B9. Forms of vitamin B9 that occur in minimally processed foods, sometimes referred to as "food folates", require digestion by enzymatic hydrolysis prior to absorption whereas folic acid does not. Some vitamins have toxic effects when consumed in excess amounts and certain vitamers have a greater potential for toxicity compared to other forms of the same vitamin. For example, hypervitaminosis A is a toxicity syndrome caused by excess consumption of retinoid vitamers of vitamin A such as retinol, retinal, and retinoic acid. In contrast, provitamin A carotenoids such as beta-carotene are not associated with these toxic effects. Nicotinic acid and nicotinamide are two vitamers of vitamin B3 that exhibit differences in metabolism. Large, pharmaceutical doses of the nicotinic acid are used under medical supervision as a treatment for hypercholesterolemia.
Compared with non-parents, parents with children have lower levels of well-being and life satisfaction until children move out of the household, at which point parents have higher well-being and satisfaction. In addition, parents report more feelings of depression and anxiety than non-parents. However, when adults without children are compared to empty nest parents, parenthood is positively associated with emotional well-being. People found parenthood to be more stressful in the 1970s than they did in the 1950s. This is thought to be because of social changes in regards to employment and marital status. Males apparently become less happy after the birth of a child due to added economic pressure and taking on the role of being a parent. A conflict between partners can arise when the couple does not desire traditional roles, or has an increasing number of roles. Unequal responsibilities of child-rearing between men and women account for this difference in satisfaction. Fathers who worked and shared an equal part in child-raising responsibilities were found to be the least satisfied. Research shows that single parents have higher levels of distress and report more mental health problems than married persons. Researchers implemented the Huta & Ryan Scale: Four Eudaimonic Measurement Questionnaire to analyze the participants eudaimonic motives, through motivation towards activities. The investigation was conducted on Canadian university undergraduates. The four eudaimonic pursuits as described by Huta & Ryan are:
Solid-liquid extraction based ambient ionization is based on the use of a charged spray, for example electrospray to create a liquid film on the sample surface. Molecules on the surface are extracted into the solvent. The action of the primary droplets hitting the surface produces secondary droplets that are the source of ions for the mass spectrometer. Desorption electrospray ionization (DESI) is one of the original ambient ionization sources and uses an electrospray source to create charged droplets that are directed at a solid sample. The charged droplets pick up the sample through interaction with the surface and then form highly charged ions that can be sampled into a mass spectrometer. Desorption atmospheric pressure photoionization (DAPPI) is a solid-liquid extraction ambient ionization method that enables the direct analysis of samples deposited on surfaces by means of a jet of hot solvent vapour and ultraviolet light. The hot jet thermally desorbs the sample from a surface and the vaporized sample is ionized by a vacuum ultraviolet light and consequently sampled into a mass spectrometer.
== Film == On February 6, 2013, while speaking at the 2013 DICE conference about storytelling in games and film, J. J. Abrams and Gabe Newell announced that they had plans for a game and a film collaboration. Abrams said, "There's an idea we have for a game that we'd like to work with Valve on," while Newell said, "We're going to figure out if we can make a Portal movie or Half-Life movie together". In an interview in March 2016, Abrams stated that while he has been working on many other projects since, he still has plans to direct these films in the future, with both films in the writing stage.
=== Naturally occurring isotope variation === Natural processes result in broad variations in the D/H ratio (DHR) in different pools of hydrogen. KIEs and physical changes such as precipitation and evaporation lead to these observed variations. Seawater varies slightly, between 0 and −10 per mil, while atmospheric water can vary between about −200‰ to +100‰. Biomolecules synthesized by organisms, retain some of the D/H signature of the water which they were grown on, plus a large fractionation factor which can be as great as several hundred ‰. Large D/H differences, of thousands of ‰, can be found between Earth and other planetary bodies such as Mars, likely due to variations in isotope fractionation during planet formation and the loss of hydrogen into space.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.